|
|
Position:
Principal Research Scientist - DMPK
Employer:
Aligos Therapeutics
Description:
Aligos Therapeutics, Inc. is a biotechnology company located in South San Francisco, California that is developing novel medicines to treat liver diseases in virology, inflammation/fibrosis, and oncology. Aligos is pursuing the development of both oligonucleotide-based and small molecule therapeutics, each addressing major commercial market opportunities.
At Aligos, our science is the key to our success with the ultimate goal of improving patients' quality of life. Our pipeline of developing novel compounds and investigative therapies reflects our commitment to bring innovative products to patients with unmet needs in the area of liver diseases. This is an exciting opportunity to become an employee a high-energy Research and Development company. We are looking for an enthusiastic person who understands and appreciates the entrepreneurial environment and who is willing to do what it takes to contribute to the success of the company.
Position Summary:
The Principal Research Scientist - DMPK will be responsible for providing DMPK expertise for new chemical entities, small molecule, and oligonucleotides, as a project representative on multi-disciplinary drug discovery and development teams. The position will have high visibility within the company and is expected to contribute directly to the company’s goals and objectives.
Qualifications/Experience:
Essential Responsibilities:
- Work closely with nonclinical discovery scientists, clinicians, and cross-functional project team members. Participate as a functional representative on discovery/development project teams.
- Provide leadership and guide discovery project teams for candidate selection, develop and drive DMPK strategies for lead optimization, and solving ADME-related issues. Design, conduct, and interpret in vitro and in vivo DMPK studies.
- Determine PK parameters for nonclinical studies using WinNonlin and assist with the application of modeling approaches (in silico, PK, PBPK) to support human pharmacokinetics and dose predictions, quantitative risk assessment of drug-drug interactions.
- Support GLP toxicology and clinical studies, monitor GLP bioanalysis, and CRO management.
- Monitor methods development, validation, sample analysis, and review and approve reports.
- Generate, analyze and present data, both orally and as written reports.
- Author and review various regulatory documents and interact with worldwide regulatory authorities.
Education and Experience:
- PhD or Pharm D. in Pharmacokinetics, Pharmaceutical Sciences, or related field with a specific focus on small molecule and oligonucleotide pharmacokinetics and metabolism with 5+ years of relevant industry experience.
- Extensive understanding of DMPK principles. A proven track record of supporting drug discovery and development as a functional representative on multidisciplinary project teams, authoring regulatory documents, supporting worldwide regulatory filings and interactions.
- Proven skills in pharmacokinetic data analysis using Phoenix WinNonlin.
- Knowledge of GLP, GCP, drug development and regulatory guidelines is required.
Preferred Education and Experience:
- Familiarity with NONMEM, SimCyp and/or Gastroplus PBPK modeling is nice to have.
Physical Requirements
- It is expected that the employee is able to sit/stand at a desk and have full use of a computer through its standard input devices (e.g., mouse and keyboard).
EEO Statement:
Aligos Therapeutics, Inc. is an Equal Opportunity Employer. We do not discriminate against qualified applicants based upon any protected group status, including but not limited to race, religion, color, creed, sex (including breastfeeding and related conditions), gender identity/gender expression, pregnancy (including childbirth and related conditions), national origin, ancestry, age, marital status, military or veteran status, sexual orientation, genetic information, physical or mental disability or medical condition as defined by applicable equal opportunity laws.
Location:
South San Francisco
Contact:
vgohil@aligos.com
Post Date:
6/25/2021 8:52:58 AM
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Submit a Text Ad
|